A modified scoring of the NCCN-IPI is more accurate in the elderly and is improved by albumin and β2-microglobulin

British Journal of Haematology

Volumn 168, Issue 2, 2015, Pages 239-245

  Melchardt, Thomas ^a   Troppan, Katharina ^b   Weiss, Lukas ^a   Hufnagl, Clemens ^a   Neureiter, Daniel ^a   Tränkenschuh, Wolfgang ^a   Hopfinger, Georg ^a   Magnes, Teresa ^a   Deutsch, Alexander ^b   Neumeister, Peter ^b   Hackl, Hubert ^c   Greil, Richard ^a   Pichler, Martin ^d   Egle, Alexander ^a  

^a PARACELSUS MEDICAL UNIVERSITY   (Austria)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Albumin; Diffuse large B cell lymphoma; Elderly; NCCN IPI; 2 microglobulin

Indexed keywords

ALBUMIN; BETA 2 MICROGLOBULIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISOLONE; RITUXIMAB; VINCRISTINE; ALBUMINOID;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; HIGH RISK PATIENT; HUMAN; INSTRUMENT VALIDATION; INTERNATIONAL PROGNOSTIC INDEX; LARGE CELL LYMPHOMA; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; NATIONAL COMPREHENSIVE CANCER NETWORK INTERNATIONAL PROGNOSTIC INDEX; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; AGE; BLOOD; DISEASE FREE SURVIVAL; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PROCEDURES; PROGNOSIS; SURVIVAL; VERY ELDERLY; YOUNG ADULT;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ALBUMINS; BETA 2-MICROGLOBULIN; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84923788013     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13116     Document Type: Article

References (14)

1. Aapro, M., Bernard-Marty, C., Brain, E.G., Batist, G., Erdkamp, F., Krzemieniecki, K., Leonard, R., Lluch, A., Monfardini, S., Ryberg, M., Soubeyran, P. & Wedding, U. (2011) Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper. Annals of Oncology, 22, 257-267.
2. Cowan, R.A., Jones, M., Harris, M., Steward, W.P., Radford, J.A., Wagstaff, J., Deakin, D.P. & Crowther, D. (1989) Prognostic factors in high and intermediate grade non-Hodgkin's lymphoma. British Journal of Cancer, 59, 276-282.
3. Fridrik, M.A., Petzer, A.L., Keil, F., Willenbacher, W., Jaeger, U., Lang, A., Burgstaller, S., Andel, J., Krieger, O., Oberaigner, W. & Greil, R. (2011) Non-pegylated liposomal encapsulated doxorubicin reduces cardiotoxicity in 1st line treatment of diffuse large B-cell lymphoma (DLBCL). Final results of a randomized trial. Blood, 118, 1149.
4. Gönen, M. & Heller, G. (2005) Concordance probability and discriminatory power in proportional hazards regression. Biometrika, 92, 965-970.
5. Gutierrez-Garcia, G., Cardesa-Salzmann, T., Climent, F., Gonzalez-Barca, E., Mercadal, S., Mate, J.L., Sancho, J.M., Arenillas, L., Serrano, S., Escoda, L., Martinez, S., Valera, A., Martinez, A., Jares, P., Pinyol, M., Garcia-Herrera, A., Martinez-Trillos, A., Gine, E., Villamor, N., Campo, E., Colomo, L. & Lopez-Guillermo, A. (2011) Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Blood, 117, 4836-4843.
6. Johnson, P.W., Whelan, J., Longhurst, S., Stepniewska, K., Matthews, J., Amess, J., Norton, A., Rohatiner, A.Z. & Lister, T.A. (1993) Beta-2 microglobulin: a prognostic factor in diffuse aggressive non-Hodgkin's lymphomas. British Journal of Cancer, 67, 792-797.
7. Melchardt, T., Weiss, L., Hufnagl, C., Neureiter, D., Kemmerling, R., Morre, P., Boekstegers, A., Hopfinger, G., Auberger, J., Steinkirchner, S., Pleyer, L., Greil, R. & Egle, A. (2014) Treatment of aggressive B-cell lymphoma in elderly patients: Influence of SNPs affecting pharmacodynamics of chemotherapeutics. Leukemia & Lymphoma, 25, 1-8.
8. Meyer, P.N., Fu, K., Greiner, T.C., Smith, L.M., Delabie, J., Gascoyne, R.D., Ott, G., Rosenwald, A., Braziel, R.M., Campo, E., Vose, J.M., Lenz, G., Staudt, L.M., Chan, W.C. & Weisenburger, D.D. (2011) Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. Journal of Clinical Oncology, 29, 200-207.
9. Morton, L.M., Wang, S.S., Devesa, S.S., Hartge, P., Weisenburger, D.D. & Linet, M.S. (2006) Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood, 107, 265-276.
10. Sehn, L.H., Berry, B., Chhanabhai, M., Fitzgerald, C., Gill, K., Hoskins, P., Klasa, R., Savage, K.J., Shenkier, T., Sutherland, J., Gascoyne, R.D. & Connors, J.M. (2007) The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood, 109, 1857-1861.
11. Shenoy, P.J., Malik, N., Nooka, A., Sinha, R., Ward, K.C., Brawley, O.W., Lipscomb, J. & Flowers, C.R. (2011) Racial differences in the presentation and outcomes of diffuse large B-cell lymphoma in the United States. Cancer, 117, 2530-2540.
12. Steward, W.P., Todd, I.D., Harris, M., Jones, J.M., Blackledge, G., Wagstaff, J., Anderson, H., Wilkinson, P.M. & Crowther, D. (1984) A multivariate analysis of factors affecting survival in patients with high-grade histology non-Hodgkin's lymphoma. European Journal of Cancer & Clinical Oncology, 20, 881-889.
13. Zhou, Z., Sehn, L.H., Rademaker, A.W., Gordon, L.I., Lacasce, A.S., Crosby-Thompson, A., Vanderplas, A., Zelenetz, A.D., Abel, G.A., Rodriguez, M.A., Nademanee, A., Kaminski, M.S., Czuczman, M.S., Millenson, M., Niland, J., Gascoyne, R.D., Connors, J.M., Friedberg, J.W. & Winter, J.N. (2014) An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood, 123, 837-882.
14. Ziepert, M., Hasenclever, D., Kuhnt, E., Glass, B., Schmitz, N., Pfreundschuh, M. & Loeffler, M. (2010) Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20 + B-cell lymphoma in the rituximab era. Journal of Clinical Oncology, 28, 2373-2380.